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Identifying the genetic variants that increase the risk of type 2 diabetes (T2D) in humans has
been a formidable challenge. Adopting a genome-wide association strategy, we genotyped 1161
Finnish T2D cases and 1174 Finnish normal glucose-tolerant (NGT) controls with >315,000
single-nucleotide polymorphisms (SNPs) and imputed genotypes for an additional >2 million
autosomal SNPs. We carried out association analysis with these SNPs to identify genetic variants
that predispose to T2D, compared our T2D association results with the results of two similar studies,
and genotyped 80 SNPs in an additional 1215 Finnish T2D cases and 1258 Finnish NGT controls.
We identify T2D-associated variants in an intergenic region of chromosome 11p12, contribute
to the identification of T2D-associated variants near the genes IGF2BP2 and CDKAL1 and the
region of CDKN2A and CDKN2B, and confirm that variants near TCF7L2, SLC30A8, HHEX, FTO,
PPARG, and KCNJ11 are associated with T2D risk. This brings the number of T2D loci now confidently
identified to at least 10.
Type 2 diabetes (T2D) is a disease charac-terized by insulin resistance and impairedpancreatic beta-cell function that affects
>170 million people worldwide (1). With first-
degree relatives having ~3.5 times as much risk
as compared to individuals in the general middle-
aged population (2), hereditary factors, together
with lifestyle and behavioral factors, play an
important role in determining T2D risk (3). To
date, intense efforts to identify genetic risk factors
in T2D have met with only limited success. This
study, reports from our collaborators (4–6), and
the recently published work of Sladek et al. (7)
describe results of genome-wide association
(GWA) studies that further define the genetic
architecture of T2D and identify biological path-
ways involved in T2D pathogenesis.
We genotyped 1161 Finnish T2D cases and
1174 Finnish NGTcontrols on 317,503 SNPs on
the Illumina HumanHap300 BeadChip in stage
1 of a two-stage GWA study of T2D (8). These
samples are from the Finland–United States In-
vestigation of Non–Insulin-Dependent Diabetes
Mellitus Genetics (FUSION) (9, 10) and Finrisk
2002 (11) studies (tables S1 and S2A). Among the
317,503 GWA SNPs, 315,635 had ≥10 copies of
the less common allele [minor allele frequency
(MAF) > 0.002] and passed quality-control crite-
ria (8). We tested these 315,635 SNPs for asso-
ciationwith T2D using amodel that is additive on
the log-odds scale (Table 1 and tables S3 and S4)
(8). We observed a modest excess (41 observed
versus 31.6 expected; P = 0.19) of SNPs with
P values < 10−4 (fig. S1). These results argue
against the existence of multiple common SNPs
with a large impact on T2D disease risk but are
consistent with the presence of multiple common
SNPs that each confer modest risk. The results
also suggest that the matching of cases and con-
trols by birth province, sex, and age (8) has been
successful; in support of this conclusion, the
genomic control (12) correction value is 1.026.
Analysis of our Illumina HumanHap300 data
allowed us to query much of the known SNP
variation in the genome. To increase this pro-
portion, we developed an imputation method
(8, 13) that uses genotype data and linkage dis-
equilibrium (LD) information from the HapMap
Centre d’Etude du Polymorphisme Humain
(Utah residents with ancestry from northern and
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Table 1. Confirmed T2D susceptibility loci based on all available data from the FUSION, DGI, and WTCCC/UKT2D samples.
Position
Risk
allele /
nonrisk
FUSION
Stage 1 + 2
control
risk
allele
FUSION stage 1 FUSION stage 2 FUSION stage 1 + 2 DGI All Data WTCCC/UKT2D All Data
FUSION-DGI-
WTCCC/UKT2D
All Data
Total
sample
size for
80%
power**FUSION Chr (bp) Genes allele freq.
OR
(95% CI) P
OR
(95% CI) P
OR
(95% CI) P
OR
(95% CI) P
OR
(95% CI) P
OR
(95% CI) P
New T2D Loci
rs4402960 3 186,994,389 IGF2BP2 T/G 0.30
1.28
(1.13–1.45) 1.2×10–4
1.08
(0.96–1.22) 0.22
1.18
(1.08–1.28) 2.1×10–4
1.17
(1.11–1.23) 1.7×10–9
1.11
(1.05–1.16) 1.6×10–4
1.14
(1.11–1.18) 8.9×10–16 ~4300
rs7754840* 6 20,769,229 CDKAL1 C/G 0.36
1.16
(1.02–1.30) 0.021
1.08
(0.96–1.22) 0.20
1.12
(1.03–1.22) 0.0095
1.08
(1.03–1.14) 2.4×10–3
1.16
(1.10–1.22) 1.3×10–8
1.12
(1.08–1.16) 4.1×10–11 ~5300
rs10811661 9 22,124,094 CDKN2A/B T/C 0.85
1.17
(0.98–1.39) 0.082
1.22
(1.04–1.44) 0.015
1.20
(1.07–1.36) 0.0022
1.20
(1.12–1.28) 5.4×10–8
1.19
(1.11–1.28) 4.9×10–7
1.20
(1.14–1.25) 7.8×10–15 ~3900
rs9300039† 11 41,871,942 C/A 0.89
1.52
(1.24–1.87) 6.0×10–5
1.45
(1.19–1.77) 2.7×10–4
1.48
(1.28–1.71) 5.7×10–8
1.16¶
(0.95–1.42) 0.12
1.13#
(0.99–1.29) 0.068
1.25
(1.15–1.37) 4.3×10–7 ~3400
rs8050136 16 52,373,776 FTO A/C 0.38
1.03
(0.92–1.16) 0.58
1.18
(1.05–1.33) 0.0063
1.11
(1.02–1.20) 0.016
1.03¶
(0.91–1.17) 0.25
1.23
(1.18–1.32) 7.3×10–14
1.17
(1.12–1.22) 1.3×10–12 ~2700
Previously published T2D association
rs1801282 3 12,368,125 PPARG C/G 0.82
1.30
(1.11–1.53) 0.0011
1.08
(0.93–1.26) 0.33
1.20
(1.07–1.33) 0.0014
1.09
(1.01–1.16) 0.019
1.23#
(1.09–1.41) 0.0013
1.14
(1.08–1.20) 1.7×10–6 ~6400
rs13266634 8 118,253,964 SLC30A8 C/T 0.61
1.22
(1.08–1.38) 0.0010
1.14
(1.02–1.28) 0.026
1.18
(1.09–1.29) 7.0×10–5
1.07
(1.0–1.16) 0.047
1.12
(1.05–1.18) 7.0×10–5
1.12
(1.07–1.16) 5.3×10–8 ~5100
rs1111875‡ 10 94,452,862 HHEX C/T 0.52
1.13
(1.01–1.27) 0.039
1.06
(0.94–1.19) 0.34
1.10
(1.01–1.19) 0.026
1.14
(1.06–1.22) 1.7×10–4
1.13
(1.07–1.19) 4.6×10–6
1.13
(1.09–1.17) 5.7×10–10 ~4200
rs7903146§ 10 114,748,339 TCF7L2 T/C 0.18
1.39
(1.20–1.61) 1.2×10–5
1.30
(1.12–1.50) 3.5×10–4
1.34
(1.21–1.49) 1.3×10–8
1.38
(1.31–1.46) 2.3×10–31
1.37#
(1.25–1.49) 6.7×10–13
1.37
(1.31–1.43) 1.0×10–48 ~1000
rs5219|| 11 17,366,148 KCNJ11 T/C 0.46
1.20
(1.07–1.36) 0.0022
1.04
(0.92–1.16) 0.55
1.11
(1.02–1.21) 0.013
1.15
(1.09–1.21) 1.0×10–7
1.15#
(1.05–1.25) 0.0013
1.14
(1.10–1.19) 6.7×10–11 ~3700
Total sample size 2,335 2,473 4,808 13,781 13,965 32,544
Number of cases/controls 1,161/1,174 1,215/1,258 2,376/2,432 6,529/7,252 5,681/8,284 14,586/17,968
*rs10946398 WTCCC/UKT2D (r2 = 1). †Multimarker tag for rs9300039 DGI and rs1514823 WTCCC/UKT2D (r2 = 0.965). ‡rs5015480 WTCCC GWA only (r2 = 1). §rs7901695 WTCCC/UKT2D (r2 = 0.849). ||rs5215 WTCCC/UKT2D (r2 =
0.995). ¶DGI GWA samples. #WTCCC GWA samples. **Approximate total sample size for 80% power to detect T2D SNP association at significance level 0.05 is based on the FUSION control risk allele frequency and the risk ratio calculated from
FUSION-DGI-WTCCC/UKT2D all-data analyses, assuming 0.10 T2D prevalence. The sample sizes vary slightly from those of (4) because study-specific allele frequencies were used in the calculations.
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western Europe) (CEU) samples to predict
genotypes of autosomal SNPs not genotyped in
our subjects. A total of 2.09 million HapMap
CEU SNPs (14) had imputed MAF >1% in
FUSION and passed our imputation quality-
control criteria. In the HapMap CEU sample,
imputed SNPs passing these criteria increased
coverage of SNPs with MAF >1% from 71.9 to
89.1% at an r2 threshold of 0.8.
To increase the statistical power to detect T2D
predisposing variants, we compared our stage
1 results to GWA results from the Diabetes
Genetics Initiative (DGI) and theWellcome Trust
Case Control Consortium (WTCCC). We
selected 82 SNPs for FUSION stage 2 follow-
up genotyping based on evidence from: (i)
FUSION-genotyped and FUSION-imputed
SNPs; (ii) a combined analysis of GWA results
from FUSION, DGI, and WTCCC; and (iii)
previous T2D association results. For (i) and (ii),
we used a prioritization algorithm that advan-
taged SNPs based on genome annotation (8)
(table S7) and gave preference to genotyped
SNPs over nearby imputed SNPs. We success-
fully genotyped 80 of the 82 SNPs in our stage 2
sample of 1215 Finnish T2D cases and 1258
Finnish NGTcontrols (8) (table S2B) and carried
out joint analysis of the combined FUSION
stage 1 + 2 sample (table S5). DGI (4) and
United Kingdom T2D Genetics Consortium
(UKT2D) (5) investigators also followed up
DGI and WTCCC GWAs by genotyping rep-
lication samples.
We confirmed well-established T2D asso-
ciations with TCF7L2, PPARG, and KCNJ11
(Table 1) (15–18). SNPs in TCF7L2 reached
genome-wide significance in the FUSION stage
1 + 2 sample [odds ratio (OR) = 1.34, P = 1.3 ×
10−8] and in the FUSION-DGI-WTCCC/
UKT2D “all-data” (i.e., all GWA and follow-up
samples) meta-analysis (OR = 1.37, P = 1.0 ×
10−48) (Table 1 and table S5).PPARGPro12→Ala12
(rs1801282) and KCNJ11 Glu23→Lys23 (rs5219)
were not genotyped in the FUSION GWA, but
nearby SNPs showed some evidence for T2D
association, as did the imputed genotypes for the
coding variants. All-data meta-analysis resulted
in genome-wide significant T2D association
with KCNJ11 Glu23→Lys23 (OR = 1.14, P =
6.7 × 10−11) and strong evidence for PPARG
Pro12→Ala12 (OR = 1.14, P = 1.7 × 10−6). The
PPARG and KCNJ11 results emphasize the value
of combining data across studies and suggest that
other T2D-associated loci remain to be found.
The combined samples from the three studies
provide evidence for seven additional T2D loci.
For the first three of these loci, we had strong
evidence in the FUSION stage 1 GWA data and,
for the latter four, our FUSION stage 1 evidence
was more modest.
A cluster of variants in the IGF2BP2 (insulin-
like growth factor 2 mRNA binding protein 2)
region was associated with T2D in our stage
1 sample (e.g., rs1470579 with OR = 1.27, P =
1.6 × 10−4) (Fig. 1A). The all-data meta-analysis
for rs4402960 resulted in genome-wide signifi-
cance (OR = 1.14, P= 8.9 × 10−16). Including the
rs4402960 genotype as a covariate essentially
eliminates evidence for T2D association for other
variants in the cluster (Fig. 1A), which is
consistent with all SNPs representing the same
T2D-predisposing variant(s). IGF2BP2 is a
paralog of IGF2BP1, which binds to the 5′
untranslated region of the insulin-like growth
factor 2 (IGF2) mRNA and regulates IGF2
translation (19). IGF2 is a member of the insulin
family of polypeptide growth factors involved in
the development, growth, and stimulation of
Fig. 1. Plots of T2D association and LD in FUSION stage 1 samples for
regions surrounding IGF2BP2 (A) and rs9300039 (B). (A) and (B) each contain
six panels. The top panels display RefSeq genes; there are none in the
rs9300039 region. The second panels (i.e., directly below the top panels) show
the T2D association –log10 P values in FUSION stage 1 samples for SNPs
genotyped in the GWA panel (closed blue circles) or imputed (open blue
circles). The third panels show T2D association –log10 P values for each SNP in
a logistic regression model correcting for the reference SNP [indicated by the
red circle for rs4402960 in (A) and for rs9300039 in (B)]. SNP rs7480010,
reported by Sladek et al. (7), is also labeled in the rs9300039 plot (B) (green
circle). A decrease in the –log10 P value from the second to the third panels
indicates that the association signal of the tested SNPs can be explained, at
least in part, by the reference SNP. In both regions, the reference SNP was
chosen for convenience; the choice of another strongly associated SNP nearby
would have resulted in a similar picture. The fourth panels show recombination
rate in centimorgans per megabase for the HapMap CEU sample (14). The fifth
and sixth panels show LD r2 and D' based on FUSION stage 1–genotyped and
FUSION stage 1–imputed data.
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insulin action. The most strongly associated
IGF2BP2 SNPs are located in a 50-kb region
within intron 2 (Fig. 1A); diabetes-predisposing
variants may therefore affect regulation of
IGF2BP2 expression.
SNP rs13266634, a nonsynonymous
Arg325→Trp325 variant in the pancreatic beta-
cell–specific zinc transporter SLC30A8 (20),
showed (through our annotation-based algorithm)
evidence for T2D association in stage 1 (Table 1
and fig. S2). Modest evidence in stage 2 resulted
in stronger evidence in our stage 1 + 2 sample
(OR = 1.18, P = 7.0 × 10−5) (Table 1 and table
S5). Subsequent DGI and UKT2D genotyping
resulted in strong evidence in the combined sam-
ples (OR = 1.12, P= 5.3 × 10−8). Sladek et al. (7)
recently reported independent T2D association
evidence with the same allele in two French
samples (P = 1.8 × 10−5 and P = 5.0 × 10−7).
SLC30A8 transports zinc from the cytoplasm
into insulin secretory vesicles (20, 21), where
insulin is stored as a hexamer bound with two
Zn2+ ions before secretion (22). Variation in
SLC30A8may affect zinc accumulation in insulin
granules, affecting insulin stability, storage, or
secretion. In high-glucose conditions, overex-
pression of SLC30A8 in insulinoma (INS-1E)
cells enhanced glucose-induced insulin secretion
(21).
SNP rs9300039 in an intergenic region on
chromosome 11 showed evidence for T2D asso-
ciation in stage 1 (Table 1 and Fig. 1B); geno-
typing our stage 2 sample resulted in near
genome-wide significance in our stage 1 + 2
sample (OR = 1.48, P = 5.7 × 10−8) (Table 1 and
tables S3 and S5). In the WTCCC and DGI
scans, the nearby SNP rs1514823 (r2 = 0.97 with
rs9300039) provided weak evidence for T2D
association with the appropriate allele; com-
bining results across all three studies gave OR =
1.25 and P = 4.3 × 10−7. Fifty-six imputed SNPs
and two more genotyped SNPs spanning 219 kb
are in LD with rs9300039 and show substantial
evidence for T2D association (P < 10−4) in our
stage 1 sample (table S3 and Fig. 1B). Including
the genotype for rs9300039 as a covariate es-
sentially eliminates evidence for T2D association
with the remaining SNPs (Fig. 1B). This region
includes three sets of spliced Expressed
Sequence Tags but no annotated genes. The
identification of a T2D-associated variant >1 Mb
from the nearest annotated gene highlights the
value of a genome-wide approach. Sladek et al.
(7) reported strongly associated SNPs in two
nearby regions on chromosome 11. SNP
rs7480010 near hypothetical gene LOC387761
is 331 kb centromeric to rs9300039. LD between
rs9300039 and rs7480010 is essentially zero
(r2 = 0.00063 and D' = 0.036), and rs7480010
showed little evidence for association in our stage
1 + 2 sample (OR = 1.03, P = 0.54). Sladek et al.
(7) also reported T2D association with three
intronic variants of EXT2, located ~2.4 Mb
centromeric of rs9300039; we found no evidence
for association with EXT2 SNPs.
SNP rs4712523, located within intron 5 of
CDKAL1, showed modest evidence for T2D as-
sociation in our FUSION stage 1 sample, which
strengthened slightly in our combined stage 1 + 2
sample (OR = 1.12, P = 0.0073) (table S5).
Nearby SNPs in strong LD with rs4712523
including rs7754840 showed modest evidence
for T2D association in the DGI scan and
considerably stronger evidence in the WTCCC
scan. Including strong DGI and UKT2D repli-
cation data resulted in genome-wide significance
(OR = 1.12, P = 4.1 × 10−11 for rs7754840) in the
all-datameta-analysis (Table 1). CDKAL1 [cyclin-
dependent kinase 5 (CDK5) regulatory subunit
associated protein–1–like 1] shares protein do-
main similarity with CDK5 regulatory subunit–
associated protein 1 (CDK5RAP1), which spe-
cifically inhibits activation of CDK5 by CDK5
regulatory subunit 1 (CDK5R1) (23). Using
quantitative reverse transcription polymerase
chain reaction analysis of a panel of RNA
samples from human tissues and cells, we
detected the highest expression of CDKAL1 in
skeletal muscle and brain cells, as well as in 293T
andHepG2 cells (fig. S3A). The associated SNPs
within intron 5, or SNPs in LD with them, may
regulate expression of CDKAL1 and so affect the
expression of CDK5. CDK5 and CDK5R1 ac-
tivity is influenced by glucose and may influence
beta-cell processes (24, 25); overactivity of
CDK5 in the pancreas may lead to beta-cell de-
generation, especially under glucotoxic condi-
tions (26).
SNP rs10811661 near cyclin-dependent ki-
nase inhibitors CDKN2A and CDKN2B showed
modest evidence for T2D association in our
stage 1 + 2 sample (OR = 1.20, P = 0.0022)
(Table 1 and table S5) and showed genome-wide
significance in the all-data meta-analysis (OR =
1.20, P = 7.8 × 10−15). SNP rs10811661 is
located upstream of CDKN2A and CDKN2B,
may have a long-range effect on one of these
genes, or may influence a gene not yet an-
notated. CDKN2A and CDKN2B inhibit the
activity of CDK4 and CDK6. In mice, Cdk4
activity has been shown to influence beta-cell
proliferation and mass, with loss of Cdk4
leading to diabetes (27, 28). We find CDKN2A
to be expressed at high levels in islets,
adipocytes, brain, and pancreas and at even
higher levels in 293T, HeLa, and HepG2 cells
(fig. S3B); CDKN2B is expressed in islets and
adipocytes and, to a lesser degree, in small intes-
tine, colon, 293T, and HepG2 cells (fig. S3C).
CDKN2A and CDKN2B are also tumor suppres-
sor genes and may play a role in aging (29).
SNPs rs1111875 and rs7923837 showedmod-
est evidence of T2D association in the FUSION
and DGI scans, much stronger evidence in the
WTCCC scan, and genome-wide significant evi-
dence (OR = 1.13,P= 5.7 × 10−10 for rs1111875)
in the all-data meta-analysis. These SNPs are in
LD (r2 = 0.70) in a region that includes HHEX
(hematopoietically expressed homeobox),
which is critical for development of the ventral
pancreas (30), the insulin-degrading enzyme
gene IDE, and the kinesin-interacting factor 11
gene KIF11. Sladek et al. (7) recently reported
independent genome-wide significant evidence
for T2D association with these SNPs.
The WTCCC/UKT2D groups identified evi-
dence for T2D and body mass index (BMI)
associations with a set of SNPs including
rs8050136 in the FTO region; the T2D associa-
tion appears to be mediated through a primary
effect on adiposity (5, 6, 31). We observed
modest evidence for association with T2D in
the combined FUSION stage 1 + 2 sample (OR =
1.11, P = 0.016) (Table 1 and table S5).
T2D can be a component of a larger syn-
drome of metabolic abnormalities, and we were
interested to assess the effects of T2D-related
traits on our association results. We repeated our
T2D association analysis for the 10 SNPs in
Table 1 with one of several variables included as
an additional covariate. Adjustment for BMI
strengthened T2D association with TCF7L2 and
SLC30A8, weakened association with rs9300039
and FTO, and had little effect on the other loci.
The effect of waist circumference was similar to
that of BMI; blood pressure variables had
essentially no effect.
Fig. 2. Prediction of T2D risk in the FUSION sample
with the use of 10 T2D susceptibility variants. T2D
cases and NGT controls with complete genotype data
were included in the analysis. To obtain a sample with
a T2D prevalence of ~10%, we included nine copies
of each of 2176NGT controls and one copy of each of
2102 T2D cases. The predicted risk for each in-
dividual was estimated from a logistic regression
model containing the 10 risk variants listed in Table
1. The proportion of T2D cases is shown for 20 equal
intervals of predicted T2D risk. We constructed 95%
confidence intervals (CIs) for the proportion of T2D
cases in each interval using the original sample of
2102 cases and 2176 controls. The constructed sam-
ple T2D prevalence (0.096) is shown as a horizontal
line. The proportion of T2D cases increases from
~5% in the lowest to 20% in the highest predicted
risk categories.
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We previously carried out T2D linkage anal-
ysis in the families of many of our stage 1 cases
(10). None of the 10 loci in Table 1 had large
T2D logarithm of the odds (LOD) scores,
although those for FTO and TCF7L2 were 0.63
and 0.60 and so were nominally significant.
LOD scores for six of the 10 loci were greater
than 0.2, as compared to 2.2 that would be
expected for random genome locations. This
suggests enrichment for T2D-associated loci in
regions with modest evidence of T2D linkage
(P = 0.01) but that the power of the linkage
approach was insufficient to distinguish these
signals from background noise.
The ability to construct a list of ten robust
and replicated T2D-associated loci (Table 1)
represents a landmark in efforts to identify ge-
netic variants that predispose to complex human
diseases, although the specific predisposing var-
iants and even the relevant genes remain to be
defined.We examined the combined risk of T2D
based on these 10 loci in our stage 1 + 2 sample
by constructing a logistic regression model and
predicting T2D risk for each person (8). We found
a fourfold variation in T2D risk from the lowest to
highest predicted risk groups, which is of potential
interest for a personalized preventive-medicine
program (Fig. 2). However, these predictions from
our datamay be biased as compared to predictions
based on the general population, likely owing to
the overestimation of ORs due to the “winner’s
curse,” enrichment for familial T2D cases, and
exclusion of individuals with impaired glucose
tolerance or impaired fasting glucose.
Thirty years ago, James V. Neel labeled T2D
as “the geneticist’s nightmare” (32), predicting
that the discovery of genetic factors in T2D
would be thoroughly challenging. Until recently,
his prediction has proven true. Although large
samples and collaboration among three groups
were required, we can confidently state that new
diabetes risk factors have been identified. Each
gene discovery points to a pathway that contrib-
utes to pathogenesis, and all of these proteins and
their relevant pathways represent potential drug
targets for the prevention or treatment of diabetes.
Based on the number of other interesting results
observed in these studies, it is likely that there
are additional T2D-predisposing loci to be found.
Even though much remains to be done, we are at
last awakening from Jim Neel’s nightmare.
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Complex I Binding by a Virally
Encoded RNA Regulates
Mitochondria-Induced Cell Death
Matthew B. Reeves,1* Andrew A. Davies,1 Brian P. McSharry,2
Gavin W. Wilkinson,2 John H. Sinclair1†
Human cytomegalovirus infection perturbs multiple cellular processes that could promote the
release of proapoptotic stimuli. Consequently, it encodes mechanisms to prevent cell death during
infection. Using rotenone, a potent inhibitor of the mitochondrial enzyme complex I (reduced
nicotinamide adenine dinucleotide– ubiquinone oxido-reductase), we found that human
cytomegalovirus infection protected cells from rotenone-induced apoptosis, a protection mediated
by a 2.7-kilobase virally encoded RNA (b2.7). During infection, b2.7 RNA interacted with complex I
and prevented the relocalization of the essential subunit genes associated with retinoid/interferon–
induced mortality–19, in response to apoptotic stimuli. This interaction, which is important for
stabilizing the mitochondrial membrane potential, resulted in continued adenosine triphosphate
production, which is critical for the successful completion of the virus’ life cycle. Complex I
targeting by a viral RNA represents a refined strategy to modulate the metabolic viability of the
infected host cell.
During primary infection or reactivation ofhuman cytomegalovirus (HCMV), espe-cially in the immunocompromised, the
virus is able to replicate in a number of cell types,
often resulting in life-threatening disease (1).
HCMVexhibits a relatively protracted life cycle
(upwards of 5 days) and at early times of in-
fection (12 to 24 hours) encodes a highly abun-
dant 2.7-kb RNA transcript (b2.7), accounting
for >20% of total viral gene transcription (2, 3)
of unknown function. The RNA may be asso-
ciated with mitochondria (4), and no protein
product of this RNA has ever been detected in
infected cells (3), suggesting that it functions as a
noncoding RNA (5).
We investigated the possibility that b2.7
could function as a noncoding RNA. A
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